Frontiers
US$ 27.31
pancreatitis from glp 1 GLP-1–Based Therapies: The Dilemma of Uncertainty GLP-1 isn't just an incretin
Description
Trials show up to 20% body weight reduction, raising interest in whether dual incretin pathways may also intersect with estrogen deficiency-driven fat redistribution
Other Potential Side Effects to Watch Gastroparesis (stomach paralysis) Can cause early fullness, bloating, or rare intestinal blockages
GI, gastrointestinal
GLP-1s: A long-term medication
Their success in managing both diabetes and obesity has been revolutionary, with GLP-1 RAs demonstrating substantially improved efficacy over last-generation interventions
Research peptides in Canada exist in a regulatory gray area managed by Health Canada
